HC Wainwright Lowers VolitionRx (NYSE:VNRX) Price Target to $1.50

VolitionRx (NYSE:VNRX) had its target price decreased by analysts at HC Wainwright from $2.50 to $1.50 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 374.68% from the stock’s current price.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $3.17.

VolitionRx Price Performance

Shares of VNRX traded down $0.02 on Monday, hitting $0.32. The company’s stock had a trading volume of 432,732 shares, compared to its average volume of 310,675. The company has a 50 day moving average price of $0.52 and a 200 day moving average price of $0.60. VolitionRx has a fifty-two week low of $0.31 and a fifty-two week high of $0.94. The company has a market capitalization of $34.00 million, a PE ratio of -0.87 and a beta of 1.24.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes acquired 96,153 shares of the business’s stock in a transaction dated Tuesday, October 14th. The shares were acquired at an average price of $0.51 per share, for a total transaction of $49,038.03. Following the acquisition, the director directly owned 1,062,967 shares of the company’s stock, valued at approximately $542,113.17. This trade represents a 9.95% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds acquired 110,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The shares were bought at an average price of $0.51 per share, for a total transaction of $56,100.00. Following the completion of the acquisition, the chief executive officer owned 2,534,847 shares of the company’s stock, valued at $1,292,771.97. This trade represents a 4.54% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 269,229 shares of company stock worth $139,557 in the last ninety days. 10.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VNRX. Armistice Capital LLC boosted its stake in shares of VolitionRx by 3.5% during the 2nd quarter. Armistice Capital LLC now owns 8,493,074 shares of the company’s stock worth $6,455,000 after buying an additional 286,644 shares during the last quarter. Citadel Advisors LLC increased its position in shares of VolitionRx by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock worth $224,000 after purchasing an additional 135,775 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx during the 2nd quarter worth approximately $52,000. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of VolitionRx by 42.8% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company’s stock valued at $153,000 after buying an additional 60,209 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in VolitionRx during the third quarter worth $28,000. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.